Tarsus Pharmaceuticals (NASDAQ: TARS) , Anavex Life Sciences (NASDAQ: AVXL) , and MediciNova (NASDAQ: MNOV) all had recent positive news coming out of phase 2 clinical trials that should whet investors' appetites.
Investing in a stock based mainly on a solid phase 2 trial is risky but it provides an opportunity to buy in on a potential growth stock before the crowd. These three don't have much real revenue, but all three have a promising therapy that may or may not pan out. If they do, these stocks could double in a short period of time, and buying in now offers a huge opportunity with that risk.
Image source: Getty Images.
For further details see:
3 Top Biotech Stocks to Buy Right Now